Medlab Clinical

Medlab Clinical CROIC

Delisted

The Cash Return on Invested Capital (CROIC) of Medlab Clinical (MDC.AX) as of Oct 19, 2026 is 19.50 %. In the previous year, Cash Return on Invested Capital (CROIC) was -428.68 % — a change of -104.55% (higher).

CROIC

19.50 %

YoY

-104.55%

Last updated:

Cash Return on Invested Capital (CROIC) of Medlab Clinical is 2024 19.50 % . Cash Return on Invested Capital (CROIC) of Medlab Clinical was 2023 -428.68 % . It decreases by -104.55% higher compared to the previous year.

The Medlab Clinical CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2017
-103.57 AUD
Jan 1, 2018
-20.84 AUD
Jan 1, 2019
-66.52 AUD
Jan 1, 2020
-77.67 AUD
Jan 1, 2021
-61.98 AUD
Jan 1, 2022
-101.00 AUD
Jan 1, 2023
-428.68 AUD
Jan 1, 2024
19.50 AUD
The Medlab Clinical CROIC history
YEARCROICYoY
19.50 %-104.55%
-428.68 %+324.42%
-101.00 %+62.97%
-61.98 %-20.21%
-77.67 %+16.78%
-66.52 %+219.18%
-20.84 %-79.88%
-103.57 %-26.53%
-140.97 %-43.04%
-247.51 %+165.92%
-93.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medlab Clinical Stock analysis

What does Medlab Clinical do? Medlab Clinical Ltd is an innovative biotechnology company focused on the development and commercialization of medical products and services. The company was founded in Australia in 2012 and is now based in Sydney. Since its founding, Medlab has established itself as a leading provider of diagnostic and therapeutic products. Medlab's business model consists of three different divisions. The first division is pharmaceutical development, where Medlab works on the development of new medications for the treatment of conditions such as fibromyalgia, pain, or ADHD. Medlab is particularly innovative in the development of medications based on the use of cannabinoids that are approved for medical use. The second division of Medlab is the research and development of nutritional supplements. The company works on the development of innovative products to improve general well-being and support health. An example is the nutritional supplement NRGBiotic, which contains special probiotic bacteria that help regulate the intestinal flora and thereby strengthen the immune system. The third division of Medlab is clinical diagnostics. The company offers various medical diagnostic tests, such as the test for food intolerances. This test is based on a blood sample and allows for targeted dietary changes in individuals with intolerance. Medlab aims to improve people's lives by developing and providing innovative products and services for medical care. Medlab's products are designed to promote the health and well-being of patients and customers and improve their quality of life. One outstanding product from Medlab is NanoCBD, an innovative form of cannabinoid delivery for medical purposes. The advantage of NanoCBD is that it has increased bioavailability due to the nanoparticles, resulting in faster and more effective action than conventional CBD products. Another product from Medlab is the pain medication NanaBis, which works faster and more effectively than other pain medications due to its unique formulation. Thanks to its special composition, NanaBis can also be taken by patients with severe chronic pain who do not respond to other pain medications. Medlab has established itself as a global company and is present worldwide. The company maintains partnerships and collaborations with renowned research institutions and doctors in Europe, North America, Australia, and Asia. Medlab works closely with medical professionals to ensure that the company's products and services meet the highest quality standards and meet the needs of patients and customers. Overall, Medlab Clinical Ltd has established itself as an innovative and reliable company in the medical industry. With its clear focus on the development of innovative medications, nutritional supplements, and diagnostic systems, Medlab significantly contributes to improving the healthcare system and increasing the well-being of people worldwide. Medlab Clinical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medlab Clinical stock

Cash Return on Invested Capital (CROIC) of Medlab Clinical is 19.50 % in 2024.

Cash Return on Invested Capital (CROIC) of Medlab Clinical changed from -428.68 % to 19.50 %, representing a -104.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Medlab Clinical since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Medlab Clinical with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medlab Clinical

All Key Metrics — Medlab Clinical